AMP Survey Finds that Inadequate Reimbursement Hinders Use of Molecular Diagnostics by Glenn S. Demby | May 5, 2021 | Articles, Clinical Diagnostics Insider, Diagnostic Testing and Emerging Technologies, Inside the Diagnostics Industry-dtet... This content is for Paid Members only.Login Register
New Genomic Test Can Eliminate Up to One-Third of Medically Unnecessary Prostate Cancer Biopsies by Glenn S. Demby | Mar 23, 2021 | Articles, Clinical Diagnostics Insider, Diagnostic Testing and Emerging Technologies, Emerging Tests-dtet... This content is for Paid Members only.Login Register
New Study Shows Viability of Using Ancestry to Compare Prostate Cancer Risk Across Populations by Glenn S. Demby | Feb 21, 2021 | Articles, Clinical Diagnostics Insider, Diagnostic Testing and Emerging Technologies... This content is for Paid Members only.Login Register
New Genomic Test Can Eliminate Up to One-Third of Medically Unnecessary Prostate Cancer Biopsies by Glenn S. Demby | Feb 21, 2021 | Articles, Clinical Diagnostics Insider, Diagnostic Testing and Emerging Technologies, Emerging Tests-dtet... This content is for Paid Members only.Login Register
New Study Shows Viability of Using Ancestry to Compare Prostate Cancer Risk Across Populations by Glenn S. Demby | Feb 11, 2021 | Articles, Clinical Diagnostics Insider, Diagnostic Testing and Emerging Technologies... This content is for Paid Members only.Login Register